Targeting Cognitive Impairment in Major Depressive Disorder

Chairs: Thomas Laughren, MD; Atul Mahableshwarkar, MD

This session will cover the scientific basis for considering CI in MDD as an unmet need and legitimate entity for drug development, and also important methodological issues such as optimal assessment approaches, study design, and when in the illness to study CI. Also provided will be industry perspectives from representatives of two companies that have approached this target differently, and also regulatory perspectives by representatives of both FDA and EMA.